An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Zanubrutinib (Primary) ; Obinutuzumab
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 09 Oct 2018 This trial has been Discontinued in Hungary.
- 01 Nov 2017 Status changed from planning to recruiting.
- 23 Jun 2017 New trial record